pd168393 and canertinib dihydrochloride

pd168393 has been researched along with canertinib dihydrochloride in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bridges, AJ; Denny, WA; Elliott, WL; Fry, DW; McNamara, DJ; Nelson, JM; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Vincent, PW; Zhou, H	1

Other Studies

1 other study(ies) available for pd168393 and canertinib dihydrochloride

Article	Year
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. Journal of medicinal chemistry, 2001, Feb-01, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Inhibitory Concentration 50; Mice; Phosphorylation; Pyrimidines; Quinazolines; Solubility; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured	2001

Article

Year

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

Journal of medicinal chemistry, 2001, Feb-01, Volume: 44, Issue:3

Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Inhibitory Concentration 50; Mice; Phosphorylation; Pyrimidines; Quinazolines; Solubility; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured

2001